Loading...
Loading...
Galderma Group AG/ADR
Galderma Group AG/ADR. Spoken Alpha tracks GDERF's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks GDERF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 90% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for GDERF.
curl https://api.spokenalpha.com/v1/companies/GDERF| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.41 | $2.61 | +30.8% | +0.2% | -1.1% |
| Q4 FY2026 | $3.48 | $2.55 | +36.4% | +9.5% | +11.5% |
| Q3 FY2026 | $3.53 | $2.69 | +31.3% | +8.8% | +9.0% |
| Q2 FY2026 | $3.21 | $2.57 | +24.8% | +7.0% | +8.3% |
| Q1 FY2025 | $3.40 | $2.51 | +35.5% | -0.5% | +2.1% |
| Q4 FY2025 | $3.50 | $2.62 | +33.4% | +3.1% | +1.1% |
| Q3 FY2025 | $3.82 | $2.78 | +37.4% | +3.8% | +3.0% |
| Q2 FY2025 | $3.56 | $2.71 | +31.4% | +6.2% | +7.8% |
| Q1 FY2024 | $3.69 | $2.66 | +38.9% | +6.1% | +8.9% |
| Q4 FY2024 | $3.52 | $2.63 | +33.8% | +1.8% | +2.5% |